Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
ORMP logo ORMP
Upturn stock ratingUpturn stock rating
ORMP logo

Oramed Pharmaceuticals Inc (ORMP)

Upturn stock ratingUpturn stock rating
$2.25
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

06/30/2025: ORMP (1-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Not Recommended Performance

These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.

Number of Analysts

rating

1 Analysts rated it

Very few follow this stock; limited insights, higher-risk early investing.

1 Year Target Price $3.25

1 Year Target Price $3.25

Analysts Price Target For last 52 week
$3.25Target price
Low$1.82
Current$2.25
high$3.09

Analysis of Past Performance

Type Stock
Historic Profit 15.32%
Avg. Invested days 41
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 2.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 06/30/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 91.91M USD
Price to earnings Ratio -
1Y Target Price 3.25
Price to earnings Ratio -
1Y Target Price 3.25
Volume (30-day avg) 1
Beta 1.62
52 Weeks Range 1.82 - 3.09
Updated Date 06/30/2025
52 Weeks Range 1.82 - 3.09
Updated Date 06/30/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.74

Earnings Date

Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -225%

Management Effectiveness

Return on Assets (TTM) -5.1%
Return on Equity (TTM) -18.51%

Valuation

Trailing PE -
Forward PE -
Enterprise Value -42514522
Price to Sales(TTM) 45.96
Enterprise Value -42514522
Price to Sales(TTM) 45.96
Enterprise Value to Revenue 2.86
Enterprise Value to EBITDA 0.52
Shares Outstanding 40850500
Shares Floating 32050041
Shares Outstanding 40850500
Shares Floating 32050041
Percent Insiders 13.58
Percent Institutions 19.11

Analyst Ratings

Rating 1
Target Price 3.25
Buy -
Strong Buy -
Buy -
Strong Buy -
Hold 1
Sell -
Strong Sell -
Strong Sell -

ai summary icon Upturn AI SWOT

Oramed Pharmaceuticals Inc

stock logo

Company Overview

overview logo History and Background

Oramed Pharmaceuticals Inc. was founded in 2002. It focuses on the development of oral drug delivery systems, primarily for diabetes. Its major milestone is the development of oral insulin capsules, seeking to transform diabetes treatment.

business area logo Core Business Areas

  • Oral Insulin: Development and commercialization of oral insulin capsules (ORMD-0801) for the treatment of diabetes.
  • Oral GLP-1: Development of oral GLP-1 (ORMD-0804) for treating Type 2 diabetes and other indications.

leadership logo Leadership and Structure

Nadav Kidron is the CEO. The company has a board of directors and operates with research and development, clinical trial, and administrative departments.

Top Products and Market Share

overview logo Key Offerings

  • ORMD-0801 (Oral Insulin Capsule): Oramed's lead product is an oral insulin capsule aimed at replacing insulin injections for Type 2 diabetes patients. It's currently in Phase 3 clinical trials. Market share is currently 0, as the product isn't yet on the market, but potential is huge if proven successful. Competitors include Novo Nordisk (NVO) and Eli Lilly (LLY) who offer injectable insulin products. The market addressable to Oramed would be a sub-section of the Type 2 diabetes patients using insulin.
  • ORMD-0804 (Oral GLP-1): An oral glucagon-like peptide-1 (GLP-1) receptor agonist being developed for Type 2 diabetes and other indications. This is currently in Phase 1 trials. Market share is currently 0, as the product isn't yet on the market, but it has great potential if proven successful. Competitors include Novo Nordisk (NVO) and Eli Lilly (LLY) who offer injectable and oral GLP-1 products.

Market Dynamics

industry overview logo Industry Overview

The pharmaceutical industry for diabetes treatments is highly competitive and regulated. There's a growing demand for more convenient and less invasive treatments like oral medications.

Positioning

Oramed is positioning itself as an innovator in oral drug delivery for diabetes, offering a potentially more convenient alternative to injections. It's a small company competing with larger, established pharmaceutical giants.

Total Addressable Market (TAM)

The global diabetes drug market is estimated to be over $100 billion. The oral insulin market, if Oramed's product is approved, could capture a significant portion of the injectable insulin market. It is well positioned due to ease of use.

Upturn SWOT Analysis

Strengths

  • Innovative oral drug delivery technology
  • Potential to disrupt the diabetes treatment market
  • Experienced management team in oral drug delivery

Weaknesses

  • Reliance on successful clinical trials
  • Limited financial resources compared to larger pharmaceutical companies
  • Product not yet approved by regulatory agencies
  • High cash burn rate

Opportunities

  • Partnerships with larger pharmaceutical companies
  • Expansion to other therapeutic areas beyond diabetes
  • Increasing global prevalence of diabetes
  • Growing interest in convenient oral therapies.

Threats

  • Failure to achieve positive clinical trial results
  • Regulatory hurdles and approval delays
  • Competition from existing and new diabetes treatments
  • Patent disputes

Competitors and Market Share

competitor logo Key Competitors

  • NVO
  • LLY
  • SNY

Competitive Landscape

Oramed faces intense competition from established pharmaceutical companies with greater resources and approved diabetes treatments. Its competitive advantage lies in its oral drug delivery technology, offering a more convenient alternative to injections. However, it must demonstrate clinical efficacy and safety to compete effectively.

Growth Trajectory and Initiatives

Historical Growth: Oramed's historical growth has been driven by progressing its oral insulin and oral GLP-1 programs through clinical trials. No sales have occurred yet.

Future Projections: Future growth depends on successful clinical trial outcomes, regulatory approvals, and commercialization efforts. Analyst estimates vary widely, with significant potential upside if ORMD-0801 is approved.

Recent Initiatives: Focus is on completing Phase 3 trials for ORMD-0801 and advancing ORMD-0804 to Phase 2.

Summary

Oramed Pharmaceuticals is a high-risk, high-reward company focused on revolutionizing diabetes treatment through oral insulin. Success hinges on positive clinical trial results and regulatory approval. While its innovative technology presents a significant opportunity, the company faces intense competition and financial challenges. The ability to secure partnerships and effectively commercialize products is crucial for future success.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • Oramed Pharmaceuticals Inc. SEC Filings, Investor Presentations, Company Website, Financial News Outlets

Disclaimers:

This analysis is for informational purposes only and does not constitute financial advice. Investment decisions should be made based on individual research and consultation with a qualified financial advisor. Market share estimates are approximate.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Oramed Pharmaceuticals Inc

Exchange NASDAQ
Headquaters New York, NY, United States
IPO Launch date 2006-04-21
President, CEO & Executive Chairman Mr. Nadav Kidron Esq.
Sector Healthcare
Industry Biotechnology
Full time employees -
Full time employees -

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions with a technology platform for the oral delivery of therapeutic proteins. It develops ORMD-0801, an oral insulin capsule, which is in phase III clinical trial for the treatment of individuals with diabetes. The company has license agreements with Oravax Medical Inc. to commercialize oral vaccines for COVID-19 and other novel coronaviruses. Oramed Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in New York, New York.